B8F Biofrontera

DGAP-News: Biofrontera AG: Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous
Biofrontera AG: Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results

16.04.2019 / 11:30
The issuer is solely responsible for the content of this announcement.


Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results

Leverkusen, Germany, April 16, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock
Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its
financial results for the full financial year ended December 31, 2018 on April 29, 2019.

Conference calls for shareholders and interested investors will be held on Monday, April 29, 2019 at the following times:

In German, at 10:00 am CET (4:00 am ET)
Dial-in number Germany:
Conference code: 80126608#

In English, at 2:30 pm CET (8:30 am ET)
Dial-in number USA:
Dial-in number UK:
Conference code: 86120053#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
-End-

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer


+49 (0) 214 87 63 2 0
IR UK: Seton Services
Toni Vallen

+44 (0) 207 224 8468
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas


 

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at .



16.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail:
Internet:
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 800515

 
End of News DGAP News Service

800515  16.04.2019 

fncls.ssp?fn=show_t_gif&application_id=800515&application_name=news&site_id=research_pool
EN
16/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports by Biofrontera

ResearchPool Subscriptions

Get the most out of your insights

Get in touch